Development

A partial-reprogramming therapy is dosed in a human for the first time

development2026-06-10

Claim

Life Biosciences dosed the first patient in a Phase 1 trial of ER-100, a partial-reprogramming therapy that resets aged retinal cells toward a younger state to restore sight in glaucoma, a milestone David Sinclair called moving to witness after 25 years chasing age reversal.

Reporting date: 2026-06-10 (not necessarily the event date)

Sources

Attribution and reporting linked by this record; links do not imply independent verification.

Welcome to June 10, 2026 (theinnermostloop.substack.com)

Knowledge graphopen in browser →

Reported in

Welcome to June 10, 2026

Actor

Life Biosciences

Evidence for

Supersedes

Drugs designed for other diseases keep turning out to slow aging

Referenced by

Cite or correct this record

Citation formatCitation text

A partial-reprogramming therapy is dosed in a human for the first time
Innermost Loop KB — secondary record
Reporting date: 2026-06-10
KB permalink: https://nicholsn.github.io/innermost-loop-kb/developments/2026-06-10-partial-reprogramming-reaches-a-patient
Claim: Life Biosciences dosed the first patient in a Phase 1 trial of ER-100, a partial-reprogramming therapy that resets aged retinal cells toward a younger state to restore sight in glaucoma, a milestone David Sinclair called moving to witness after 25 years chasing age reversal.
Attributed sources:
- Welcome to June 10, 2026 — https://theinnermostloop.substack.com/p/welcome-to-june-10-2026
This citation does not imply independent verification of linked-source claims.

Suggest a correction — opens a GitHub draft for you to review and submit.